Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Study in Malawi shows importance of screening HIV-positive patients for HBV co-infection and using tenofovir-containing regimens

Hepatitis B virus (HBV) genotype A1 infection is associated with poor virological control and the rapid emergence of drug resistance among people living with HIV who are

Published
14 August 2014
By
Michael Carter
Vertex to stop selling hepatitis C drug Incivek, once a blockbuster, in October

Vertex Pharmaceuticals has notified health care providers that it will stop selling its first blockbuster drug, Incivek, in about two months.

Published
13 August 2014
From
Boston Business Journal (blog)
Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices

Share Tools Comment Print Contact Author Reprint Indian drugmakers have a shot at bringing Gilead Sciences' ($GILD) hot new hepatitis C drug to their country. The California-based company is in talks with "a handful" of Indian pharmas to take Sovaldi (sofosbuvir) to that country and other developing nations at a fraction of the U.S. price.

Published
11 August 2014
From
Fierce Pharma
Why the Hepatitis Cure Sovaldi Is a Budgetary Disaster for Prisons

There is only one group in the United States with a constitutional right to medical care: prisoners. That is why the introduction of an expensive new drug to treat hepatitis C is forcing prison administrators to begin wrestling with a big dilemma — save their budgets or treat their inmates.

Published
07 August 2014
From
New York Times
What Will the new Hepatitis C Medicines do to Medicare Part D?

In the latest salvo fired over the cost of hepatitis C treatments, a new report projects that the cost of these drugs – including the Sovaldi medication sold by Gilead Sciences – will increase 2015 federal spending by Medicare Part D between $2.9 billion to $5.8 billion.

Published
05 August 2014
From
Wall Street Journal
Study predicts hepatitis C will become a rare disease in 22 years

Effective new drugs and screening would make hepatitis C a rare disease by 2036, according to a computer simulation conducted by The University of Texas MD Anderson Cancer Center and the University of Pittsburgh Graduate School of Public Health.

Published
05 August 2014
From
Eurekalert Medicine & Health
Couples-based intervention has impact on HCV incidence and risky sexual behaviour among drug-involved couples in Kazakhstan

A couples-based risk reduction intervention reduced hepatitis C virus (HCV) incidence and levels of sexual risk-taking among drug-involved couples, investigators report in the online edition of the Journal

Published
01 August 2014
By
Michael Carter
Call to EU Ministers of health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding universal access to curative hepatitis C treatment in the EU and beyond

Together with many large NGOs EATG has signed up to a Joint Declaration urging EU Ministries of health to consider compulsory licensing as a last resort to ensure access to the HCV direct-acting antivirals.

Published
30 July 2014
From
EATG
Hepatitis C annual report: progress made, but much more to do

New figures from PHE reveal hospital admissions, liver transplants and deaths from hepatitis C (HCV) have all risen in the UK.

Published
28 July 2014
From
Public Health England
Interferon-free hepatitis C treatment works for people on methadone or buprenorphine

People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen

Published
25 July 2014
By
Liz Highleyman

Filter by country